MedTrace Logo

E6/E7 mRNA Performance to Detect HSIL and Cost-effectiveness Analysis of This Screening Strategy in HIV + MSM

NCT03357991 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 355

Last updated 2017-12-07

No results posted yet for this study

Summary

This study evaluates the positive and negative predictive value of E6/E7 mRNA expression for anal HSIL and its capacity to predict incident HSIL in HIV + MSM. We also analyse the cost-effectiveness of this new screening strategy. It is an ambispective study with 355 participants and a follow-up period of 2 to 5 years.

Conditions

  • HPV - Anogenital Human Papilloma Virus Infection
  • HSIL, High Grade Squamous Intraepithelial Lesions
  • Anal Cancer
  • Hiv

Sponsors & Collaborators

  • Institut d'Investigació Biomèdica de Bellvitge

    collaborator OTHER

  • Hospital Universitari de Bellvitge

    lead OTHER

Principal Investigators

  • Daniel Podzamczer Palter · Hospital Universitari de Bellvitge

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-11
Primary Completion
2020-06-30
Completion
2020-06-30

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03357991 on ClinicalTrials.gov